Mirikizumab-Mrkz Injection shortage
Mirikizumab-Mrkz Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 17, 2026.
Eli Lilly is stopping Omvoh (mirikizumab-mrkz) 100 mg/1 mL injection, and this change may be permanent. Eli Lilly says a 200 mg/2 mL version of Omvoh will remain available after distribution of the 100 mg/1 mL ends in April 2026.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Mirikizumab-Mrkz Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Dec 22, 2025Currently in shortage2 of 2 products affected.
-
Dec 22, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27) | — | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain. | — |
| To Be Discontinued | Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27) | — | — | A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain. | — |
These rows are manufacturer reports to the FDA for Mirikizumab-Mrkz Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Mirikizumab-Mrkz Injection? options further down this page.
Why is Mirikizumab-Mrkz Injection in shortage?
Eli Lilly has made a business decision to permanently stop distributing two specific package sizes of Omvoh (mirikizumab-mrkz) — both are the 100 mg/1 mL injection versions. Distribution of these packages will end in April 2026. No specific reason beyond a business decision was shared publicly.
The good news is that Eli Lilly is not stopping Omvoh altogether. The 200 mg/2 mL injection presentations of Omvoh will continue to be made and distributed going forward.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Mirikizumab-Mrkz Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Mirikizumab-Mrkz Injection?
Mirikizumab-Mrkz injection (brand name Omvoh) is currently listed on the FDA drug-shortage list, and I want to walk you through what that means for you.
The affected strength is the 100 mg/1 mL injection. According to the reported data, this strength does not have an available source right now. The manufacturer, Eli Lilly and Co., has made a business decision to discontinue it, with distribution ending in April 2026. Because this is a discontinuation, the supply problem with the 100 mg/1 mL presentation is likely permanent. Notably, the manufacturer reports that the 200 mg/2 mL injection presentation will remain available.
Since your specific strength is being phased out, a conversation with your prescriber is the right next step.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed while you sort this out.
- Ask your pharmacy to check with wholesalers, since local stock can differ from national reports.
- Because the 100 mg/1 mL form is being discontinued, ask your prescriber or pharmacist about options — for example, whether the remaining 200 mg/2 mL presentation could fit your regimen.
This is general, manufacturer-reported information and may not match your pharmacy's actual stock. The manufacturer's contact number is listed on this page for reference; your pharmacy usually handles those calls.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Mirikizumab-Mrkz Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Mirikizumab-Mrkz Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Omvoh | MIRIKIZUMAB 100 mg/mL | Injection, Solution · Subcutaneous | Eli Lilly and Company | 00002-1442-11 |
Alternative dosage forms of Mirikizumab-Mrkz
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 4 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Omvoh 100 mg/mL | Eli | 2 syringes | — | — | FDA listed |
| Omvoh 100 mg/mL | Eli | 1 syringe | — | — | FDA listed |
| Omvoh 100 mg/mL | Eli | 2 syringes | — | — | FDA listed |
| Omvoh 100 mg/mL | Eli | 1 syringe | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Mirikizumab-Mrkz Injection — that fall in the same broad treatment class (interleukin-23 (il-23) receptor antagonist) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Mirikizumab-Mrkz Injection shortage FAQs
Is Mirikizumab-Mrkz Injection in shortage?
Which products are affected?
When will Mirikizumab-Mrkz Injection be available again?
Can I still get Mirikizumab-Mrkz somewhere?
What should I do if I take Mirikizumab-Mrkz Injection?
Still have a question about the Mirikizumab-Mrkz Injection shortage?
Ask a pharmacist about this shortage →View Mirikizumab-Mrkz Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.